Hitachi High-Technologies, QIAGEN Collaborate
News Jun 18, 2015
Under terms of the agreement, both companies will bring their unique strengths to the collaboration: Hitachi High-Technologies is recognized as a leader in industrialized instrument development and manufacturing technologies, especially for life sciences and in-vitro diagnostics, while QIAGEN brings its leadership in molecular Sample to Insight solutions for use in both the life sciences and clinical diagnostics.
Initial projects for the collaboration involve developing new automation systems based on PCR (polymerase chain reaction) and NGS (next-generation sequencing) technologies. Both parties agreed that the collaboration could be expanded in the future to involve co-commercialization of products in specific geographic markets. Further terms of the collaboration are confidential.
“QIAGEN and Hitachi High-Technologies share much the same corporate culture such as customer focus as well as a commitment to technology and quality leadership,” said Yasukuni Koga, Head of Medical Systems Sales and Marketing Div., of Hitachi High-Technologies. “We believe those are crucial for the collaboration to achieve a meaningful position in the rapidly changing and highly competitive markets of in-vitro diagnostics and life sciences, applying genetic engineering. Moreover, developing a co-commercialization collaboration with distribution and customer service in specific geographical regions would be highly accepted by customers of each company.”
“This new strategic partnership with Hitachi High-Technologies will form a very powerful platform to create new molecular testing solutions. Hitachi High-Technologies is a recognized leader in industrial automation and has a proven track record of innovation as well as a significant presence in the Asia-Pacific region,” said Thierry Bernard, Senior Vice President, Head of the Molecular Diagnostics Business Area and a member of the Executive Committee of QIAGEN. “Combining the NGS-related and other molecular know-how of QIAGEN with the instrumentation expertise of Hitachi High-Technologies will enable us to bring innovative automation solutions to customers all over the world and across the continuum from basic research through to routine molecular diagnostics.”
Algorithm Predicts Life Expectancy After Heart AttackNews
A new algorithm developed by UCLA researchers more accurately predicts which people will survive heart failure, and for how long, whether or not they receive a heart transplant. The algorithm would allow doctors to make more personalized assessments of people who are awaiting heart transplants, which in turn could enable health care providers to make better use of limited life-saving resources and potentially reduce health care costs.
Blood Test Rapidly Detects Signs of Pancreatic CancerNews
The new test can rapidly screen a drop of blood for biomarkers of pancreatic cancer, and provide results in less than an hour.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE